Johnson & Johnson (JNJ)

Currency in USD
218.01
-0.20(-0.09%)
Closed·
218.00-0.01(0.00%)
·
JNJ is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
210.50218.68
52 wk Range
141.50220.11
Key Statistics
Prev. Close
218.21
Open
211
Day's Range
210.5-218.68
52 wk Range
141.5-220.11
Volume
14.52M
Average Volume (3m)
8.72M
1-Year Change
50.0723%
Book Value / Share
32.92
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
JNJ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
212.00
Downside
-2.76%
Members' Sentiments
Bearish
Bullish
ProTips
13 analysts have revised their earnings downwards for the upcoming period

Johnson & Johnson News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Employees
138100

Johnson & Johnson SWOT Analysis


Oncology Powerhouse
Johnson & Johnson's oncology division emerges as a key growth driver, with CARVYKTI leading the charge and projections of $50 billion in oncology sales by 2030
Financial Resilience
Despite challenges, J&J reports robust Q4 2024 results with 5.9% adjusted operational sales growth, surpassing expectations and demonstrating financial stability
Strategic Expansion
J&J explores CAR-T therapies beyond oncology, venturing into autoimmune diseases and strengthening its portfolio through strategic acquisitions like V-Wave
Analyst Perspectives
Price targets range from $152 to $215, reflecting varied outlooks on J&J's growth potential amid ongoing talc litigation and upcoming Stelara biosimilar competition
Read full SWOT analysis

Johnson & Johnson Earnings Call Summary for Q4/2025

  • Johnson & Johnson reported Q4 2025 EPS of $2.46 matching forecasts, while revenue beat expectations at $24.6 billion, though stock declined 2.92% pre-market.
  • Full-year sales reached $94.2 billion with 5.3% operational growth; the company maintains $20 billion in cash and marketable securities with $19.7 billion free cash flow.
  • CEO Joaquin Duato projected the company will soon exceed $100 billion in annual revenue, with operational sales growth forecasted between 5.7-6.7% for 2026.
  • Management anticipates adjusted EPS growth of 5.5% in 2026 and targets double-digit growth by decade's end, driven by Innovative Medicine and MedTech segments.
  • Ongoing talc litigation, potential market saturation, and global supply chain disruptions were identified as key risks that could impact future performance.
Last Updated: 22/01/2026, 02:06 am
Read Full Transcript

Compare JNJ to Peers and Sector

Metrics to compare
JNJ
Peers
Sector
Relationship
P/E Ratio
19.6x30.0x−0.6x
PEG Ratio
0.29−0.190.00
Price/Book
6.6x6.1x2.6x
Price / LTM Sales
5.6x4.7x3.4x
Upside (Analyst Target)
−2.6%0.0%42.5%
Fair Value Upside
Unlock9.3%5.8%Unlock

Analyst Ratings

13 Buy
11 Hold
1 Sell
Ratings:
25 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 212.00
(-2.76% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Bernstein SocGen Group
Hold208.00-4.59%193.00Maintain09/01/2026
Stifel
Hold205.00-5.97%190.00Maintain06/01/2026
Stifel
Hold205.00-5.97%190.00Maintain06/01/2026
UBS
Buy214.00-1.84%214.00Maintain05/01/2026
Barclays
Hold217.00-0.46%197.00Maintain30/12/2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 10.35%
Dividend Yield
2.39%
Industry Median 2.47%
Annualised payout
5.20
Paid quarterly
5-Years Growth
+5.32%
Growth Streak

Earnings

Latest Release
Jan 21, 2026
EPS / Forecast
2.46 / 2.46
Revenue / Forecast
24.60B / 24.15B
EPS Revisions
Last 90 days

JNJ Income Statement

People Also Watch

388.88
MU
+6.54%
297.54
IBM
+2.12%
173.88
ORCL
-3.36%
347.75
UNH
+2.75%
294.23
ADBE
+1.33%

FAQ

What Is the J&J (JNJ) Stock Price Today?

The J&J stock price today is 218.01

What Stock Exchange Does J&J Trade On?

J&J is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for J&J?

The stock symbol for J&J is "JNJ."

Does J&J Pay Dividends? What’s The Current Dividend Yield?

The J&J dividend yield is 2.39%.

What Is the J&J Market Cap?

As of today, J&J market cap is 526.09B.

What Is J&J's Earnings Per Share (TTM)?

The J&J EPS (TTM) is 10.35.

When Is the Next J&J Earnings Date?

J&J will release its next earnings report on 13 Apr 2026.

From a Technical Analysis Perspective, Is JNJ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has J&J Stock Split?

J&J has split 6 times.

How Many Employees Does J&J Have?

J&J has 138100 employees.

What is the current trading status of J&J (JNJ)?

As of 21 Jan 2026, J&J (JNJ) is trading at a price of 218.01, with a previous close of 218.21. The stock has fluctuated within a day range of 210.50 to 218.68, while its 52-week range spans from 141.50 to 220.11.

What Is J&J (JNJ) Price Target According to Analysts?

The average 12-month price target for J&J is USD212.00, with a high estimate of USD240 and a low estimate of USD155. 13 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -2.76% Downside potential.

What Is the JNJ Premarket Price?

JNJ's last pre-market stock price is 211.84. The pre-market share volume is 377,620.00, and the stock has decreased by -6.37, or -2.92%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.